Depomed at the 2016 UBS Global Healthcare Conference (Replay)
05/23/16 at 9:00 a.m. ET
Depomed at the Bank of America Merrill Lynch 2016 Health Care Conference (Replay)
05/10/16 at 8:40 a.m. PT
Q1 2016 Depomed Earnings Conference Call (Replay)
05/05/16 at 4:30 p.m. ET
Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market FDA-approved products, NUCYNTA®ER, NUCYNTA®, Gralise®, Cambia®, Lazanda® and Zipsor®. We actively seek to expand our product portfolio by identifying product acquisition targets that fit within our pain and neurology portfolio, have lengthy periods of exclusivity and have untapped market potential.Depomed also has successfully developed and licensed its proprietary oral drug-delivery technology, Acuform®, that allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. Depomed has licensed Acuform technology to six pharmaceutical partners, and the technology is currently being used in four marketed drugs, including NUCYNTA ER and Gralise.
The following are abbreviated descriptions of Depomed’s products:
NUCYNTA® ER (tapentadol) extended release tablets indicated, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and in adult patients who have neuropathic pain associated with diabetic peripheral neuropathy (DPN) that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate;
NUCYNTA® (tapentadol) an immediate release version of tapentadol, is indicated for the management of moderate to severe acute pain in adults;
Gralise® (gabapentin), a once-daily product for the management of postherpetic neuralgia,
Cambia®(diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older,
Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain, and
Zipsor® (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults.
|Recent News||> MORE|
|Upcoming and Recent Events||> MORE|